Rectal Absorption of [Bis (acetato) ammine dichloro (cyclohexylamine)platinum(IV)](BMS-182751), a New Anti-tumor Agent, in Rats
スポンサーリンク
概要
- 論文の詳細を見る
The rectal absorption of a platinum anti-tumor agent, [bis (acetato) ammine dichloro (cyclohexylamine)platinum(IV)](BNS-182751), was investigated in rats. BMS-182751 was co-ground with various carriers to improve its poor aqueous solubility. The highest drug dissolution was observed for the co-ground mixture of BMS-182751 and low molecular (LM) gelatin (1 : 9,w/w), followed by β-cyclodextrin and polyvinylpyrrolidone. The influence of a suppository base or additive on the rectal absorption of BMS-182751 in the drug state of crystalline powder or co-ground mixture was examined in vitro using excised rat rectum. A macrogol base gave much higher BMS-182751 permeation across the rat rectum than that from a Pharmasol base. The addition of sodium caprylate or caprylic acid to the macrogol base markedly enhanced the drug permeation, and a 3% addition of sodium caprylate to the base afforded maximum drug permeation. Two rectal formulations, the co-ground mixture with LM-gelatin plus 3% sodium caprylate in macrogol and the crystalline drug alone plus 3% sodium caprylate in macrogol, as well as an oral aqueous drug suspension, were administered to rats. The C_<max> and AUC_<0-24h> values for platinum from the former suppository were 5.1-and 4.1-fold greater than those from the oral suspension, respectively. The values from the latter suppository were almost comparable to those from the suspension. These results suggest that the suppository may provide a promising therapeutic means for cancer treatment using this platinum agent.
- 公益社団法人日本薬学会の論文
- 1999-05-15
著者
-
Takahashi N
Faculty Of Pharmaceutical Sciences Okayama University
-
Tanaka M
Otsuka Pharmaceutical Co. Ltd. Tokushima Jpn
-
TANAKA Makoto
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
KUWAHARA Etsuhisa
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
SHIMIZU Takayoshi
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
CHIKAZAWA Hirotaka
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
HISADA Shinji
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
TAKAHASHI Norimitsu
Kanagawa Laboratories, Bristol-Myers Squibb K.K.,
-
Hisada Shinji
Kanagawa Laboratories Bristol-myers Squibb K.k.
-
Shimizu Takayoshi
Kanagawa Laboratories Bristol-myers Squibb K.k.
-
Kuwahara E
Kanagawa Laboratories Bristol-myers Squibb K.k.
-
Chikazawa H
Kanagawa Laboratories Bristol-myers Squibb K.k.
-
Chikazawa Hirotaka
Kanagawa Laboratories Clinical Research & Product Development Division Bristol-myers Squibb K.k.
-
Tanaka M
Kanagawa Laboratories Bristol-myers Squibb K.k.
関連論文
- INHIBITION OF PROSTAGLANDIN BIOSYNTHESIS BY A NEW ANTIINFLAMMATORY DRUG, TA-60
- Effects of Adenine-Nucleotides on the Sequence-Specificity of Origin Recognition Complex-Binding to DNA
- Effects of Methyl 9(or 10)-Hydroxy-10(or 9)-mercaptostearate and Hexanecabethioic S-Acid on Cupric Ion- or 2,2-Azo-bis(2-amidinopropane) Dihydrochloride (AAPH)-Induced Oxidation of Low Density Lipoprotein
- Thiopalmitic Acid-Mediated Fe(III)-Nitrilotriacetate Reduction an Lipid Peroxidation
- Characterization of Secretory Type IIA Phospholipase A_2(sPLA_2-IIA)as a Glycyrrhizin(GL)-Binding Protein and the GL-Induced Inhibition of the CK-II-Mediated Stimulation of sPLA_2-IIA Activity in Vitro
- Rectal Absorption of [Bis (acetato) ammine dichloro (cyclohexylamine)platinum(IV)](BMS-182751), a New Anti-tumor Agent, in Rats
- Enhanced Rectal Absorption of Amphotericin B Lyophilized with Glycyrrhizinate in Rabbits
- Acidic Phospholipids with Unsaturated Fatty Acids Inhibit the Binding of Origin Recognition Comples to Origin DNA
- Anti-tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts
- Analysis of Origin Recognition Complex in Saccharomyces cerevisiae by Use of Degron Mutants
- Uptake of CD-349 and Nitrendipine into Bovine Intrapulmonary Artery and Vein
- Enantioselective determination of sotalol enantiomers in biological fluids using high-performance liquid chromatography
- Schedule-dependent and -independent Antitumor Activity of Paclitaxel-based Combination Chemotherapy against M-109 Murine Lung Carcinoma in vivo